This amendment, sponsored by Sen. Bernie Sanders (I-VT), would impose price controls on prescription drugs through a Most Favored Nation pricing mandate. Under this approach, the federal government would tie U.S. prescription drug prices to prices paid in Europe and Canada, where government-run healthcare systems often suppress drug prices through centralized pricing decisions and restricted access. The underlying resolution sets the congressional budget for fiscal year 2026 and establishes budgetary levels for fiscal years 2027 through 2035.

While lawmakers should work to lower drug costs by combatting PBM schemes, this amendment worsens the quality of our nation's healthcare system by importing price controls from countries with socialized healthcare systems. Most Favored Nation pricing would force American drug pricing to follow foreign governments that already ration access and underpay for innovation, making it harder for manufacturers to recover the enormous investments required to develop new treatments. That makes drug development less attractive to investors and ultimately threatens the innovation pipeline patients depend on for future cures.

This amendment, sponsored by Sen. Ron Wyden (D-OR), would require the Comptroller General to study the economic consequences of private or confidential drug pricing agreements between any federal department, agency, or office and pharmaceutical manufacturers. The underlying resolution sets the congressional budget for fiscal year 2026 and establishes budgetary levels for fiscal years 2027 through 2035.

This amendment is not really about lowering costs for patients. It is another tool to pressure drug manufacturers into worse government-directed "deals," especially in the context of Most Favored Nation-style pricing that ties American drug prices to foreign countries that rely on price controls and rationed access. Using federal studies and oversight to attack confidential pricing agreements makes it harder for manufacturers to recover the investments needed to develop new treatments, makes drug development less attractive to investors, and ultimately threatens the innovation pipeline patients depend on for future cures.

This bill, the "Drug Deal Disclosure Act", sponsored by Sen. Ron Wyden (D-OR), requires HHS to publicly disclose documents, communications, contracts, meeting notes, and other records tied to certain drug pricing agreements between the federal government and drug manufacturers entered into on or after January 20, 2025. The bill specifically targets agreements involving most-favored-nation pricing, direct-to-consumer drug discounts, TrumpRx or similar platforms, tariff treatment, domestic investment commitments, CMMI demonstrations, stockpile purchasing, and FDA priority review vouchers. It also requires CBO and GAO to analyze the economic and budgetary effects of the disclosed agreements.

This is not real transparency aimed at lowering costs for patients. It is a tool to pressure drug manufacturers into even worse "deals" under most-favored-nation price controls, which tie American drug pricing to foreign countries that already rely on government price controls and rationed access. Forcing companies into politically driven pricing schemes makes it harder for manufacturers to recover the massive investments required to develop new treatments, makes drug development less attractive to investors, and ultimately threatens the innovation pipeline patients depend on for future cures.

This bill, the "Maternal Health Pandemic Response Act", sponsored by Sen. Elizabeth Warren (D-MA), authorizes $190 million for federal data collection, surveillance, and research on maternal and infant health during public health emergencies. The bill funds CDC programs, maternal mortality surveillance, PRAMS survey expansion, and NIH research, while also directing federal agencies to publish emergency maternal health data, run public health education campaigns, and create a new HHS task force on maternity care during public health emergencies.

While maternal and infant health are important priorities, this bill responds with more federal spending, more federal reporting systems, and another Washington task force. Instead of focusing on removing barriers that make maternity care harder to access, the bill expands the public health bureaucracy and uses emergency response as a vehicle for new programs and future federal recommendations on how care should be delivered. This is exactly the kind of open-ended federal expansion that drives taxpayer costs higher without fixing the underlying affordability problems in healthcare.

This bill, the "Legalizing Premium Health Care Act of 2026", sponsored by Sen. Rand Paul (R-KY), amends Medicare to let beneficiaries freely contract with eligible healthcare professionals for Medicare fee-for-service items and services without losing access to their Medicare benefits. Under the bill, a beneficiary could see a doctor or other eligible provider outside the usual Medicare participation structure, submit a claim for Medicare payment, and receive reimbursement at the standard Medicare rate, while paying any remaining difference under the private contract.

This is a patient choice bill that pushes back on Medicare rules that trap seniors in a government-controlled system even after they paid into it for decades. When doctors leave Medicare because of red tape and low reimbursement, patients should not be forced to abandon trusted physicians or pay the entire cost out of pocket. By allowing seniors to use their own Medicare benefits with the provider they choose, the bill strengthens the doctor-patient relationship and makes it easier for providers to keep serving Medicare patients.